搜尋結果
Part 1: The importance of mobility and medical affairs and its value to the organization is most definitely on the rise. “The most competitive pharma companies in the coming decade will be masters of data and digital technologies.”. So begins the June 2017 industry brief, “ Reinventing the Role of Medical Affair s ,” by Bain & Company.
- Challenges For Many South Korean Cros
- The State of Pharmacovigilance Regulation Updates in South Korea
- Cros and Service Providers Are at A Crossroads
Traditional safety workflows are inefficient, labor-intensive, and contain multiple manual, time-consuming steps. They are also cost-effective to scale, which makes it difficult to stay cost-competitive and efficiently deliver the level of service that clients expect (or demand). To grow a serviceable market, CROs and service providers need to meet...
Globally, pharmacovigilance regulations are constantly changing in terms of analyzing safety information worldwide. Increasing demand and industry competition, partnered with complex regulations and global operations makes for a complex landscape to navigate. Since South Korea became a member of the International Council for Harmonisation(ICH) in 2...
Today we are finding that globally, CROs and service providers are at a breaking point. According to industry biopharma trend reports, big pharma companies are currently outsourcing 40-45% of their activities, which is projected to grow to 60% and the outsourcing market is set to grow to $91.4B by 2028 to meet rising demands. In turn, many CROs, an...
China is aligning its regulatory environment with that of global standards with an aim to promote innovation, simplify drug development processes and to enhance the efficacy, quality and safety of the drugs approved. Read this whitepaper to learn how LifeSphere Safety MultiVigilance (ARISc), the drug safety software.
Miami, Florida, Tokyo, August 23, 2021. Asahi Kasei Pharma Corp. has selected LifeSphere® MultiVigilance as a new safety database with the purpose of building a system that supports efficiency, regulatory compliance, and global collaboration over the long term.
2018年11月27日 · November 27, 2018 – The U.S. Food and Drug Administration (FDA) has selected Booz Allen Hamilton to support development, modernization, and enhancement of the FDA Adverse Event Reporting System (FAERS). As part of this work, the Agency will deploy ArisGlobal’s LifeSphere MultiVigilance (LSMV) platform to replace part of its current ...
Digitization is sweeping the life sciences industry, disrupting traditional working practices and opening doors to better ways of collaborating, tracking and sharing documents and data, and gaining clear oversight into the product supply chain.
ArisGlobal is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere ®, integrates our proprietary cognitive computing engine to automate all core functions of the drug development lifecycle.
